Wells Fargo downgraded Health Catalyst sharply, cutting rating and price target. Wells Fargo downgraded Health Catalyst (HCAT) to Equal Weight from Overweight on March 18, slashing its price target from $5 to $1. The firm cited prolonged revenue and margin pressures expected to persist through 2027, with no clear near-term solutions in sight. This significant downgrade reflects concerns about the healthcare data analytics company's ability to improve performance despite management's focus on operational fixes under new leadership. Health Catalyst reported Q1 2026 guidance of $68-70 million in revenue and $7-8 million in Adjusted EBITDA, as the company attempts to address execution challenges and position itself for long-term growth. The substantial reduction in price target signals investor caution regarding the stock's near-term prospects.
